Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.93M, +115.7% YoY · Filed Aug 11, 2026
Neuraxis, Inc. (NRXS) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.9 million and a net loss of $2.1 million. Free cash flow was -$1.0 million. As of Jun 30, 2026 it held $8.3 million in cash and investments and $279,392 in total debt.
Revenue
$1.93M
+115.7% vs year-ago quarter
Net income
$-2.09M
-23.4% vs year-ago quarter
Operating cash flow
$-1.03M
+29.8% vs year-ago quarter
Free cash flow
$-1.04M
+30.2% vs year-ago quarter
EPS
$-0.19
+13.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
12.56M
+27.4% vs year-ago quarter
Net cash
$8.04M
Q2 FY2026
Operating margin
-144.5%
TTM
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- NRXS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carmel, IN
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1933567
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.9M | $1.6M | $968,127 | $811,414 | $894,086 |
| Operating income | -$2.1M | -$1.7M | -$1.7M | -$2.1M | -$1.7M |
| Net income | -$2.1M | -$1.8M | -$1.7M | -$2.1M | -$1.7M |
| Diluted EPS | -$0.19 | -$0.18 | -$0.18 | -$0.24 | -$0.22 |
| Operating cash flow | -$1.0M | -$1.2M | -$1.9M | -$1.4M | -$1.5M |
| Free cash flow | -$1.0M | — | -$1.9M | -$1.4M | -$1.5M |
| Total assets | $10.0M | $8.7M | $6.4M | $5.8M | $7.1M |
| Total liabilities | $3.3M | $3.0M | $3.0M | $3.5M | $2.8M |
| Stockholders' equity | $6.7M | $5.7M | $3.4M | $2.3M | $4.3M |
| Cash and investments | $8.3M | $7.1M | $5.0M | $4.4M | $6.0M |
| Total debt | $279,392 | $353,522 | $416,611 | $478,425 | $410,478 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Aug 19, 2026 | Jul 24, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 10, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 193 Neuraxis, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.